PerkinElmer, Inc. (NYSE:PKI) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 4,760,000 shares, an increase of 11.5% from the August 15th total of 4,270,000 shares. Based on an average trading volume of 672,800 shares, the short-interest ratio is presently 7.1 days. Approximately 4.3% of the company’s shares are sold short.
Several brokerages have recently commented on PKI. Wood & Company restated an “average” rating and issued a $49.00 target price on shares of PerkinElmer in a research note on Friday, July 19th. Bank of America raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 target price on the stock in a research report on Thursday, September 26th. ValuEngine cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Wednesday, July 31st. Raymond James initiated coverage on shares of PerkinElmer in a research report on Wednesday, July 10th. They set an “outperform” rating on the stock. Finally, UBS Group lifted their target price on shares of PerkinElmer from $99.00 to $101.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. Nine investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $78.63.
Shares of NYSE PKI traded up $1.50 during mid-day trading on Friday, reaching $82.00. 698,078 shares of the company were exchanged, compared to its average volume of 677,379. The company has a quick ratio of 1.31, a current ratio of 1.89 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $8.96 billion, a PE ratio of 22.71, a PEG ratio of 1.49 and a beta of 1.29. The company’s 50 day moving average price is $83.89 and its 200 day moving average price is $90.10. PerkinElmer has a 52 week low of $71.83 and a 52 week high of $103.00.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Monday, July 29th. The medical research company reported $1.00 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.01). The business had revenue of $722.50 million during the quarter, compared to the consensus estimate of $729.10 million. PerkinElmer had a return on equity of 16.07% and a net margin of 9.01%. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.91 earnings per share. On average, sell-side analysts predict that PerkinElmer will post 4.05 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 8th. Stockholders of record on Friday, October 18th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.34%. The ex-dividend date is Thursday, October 17th. PerkinElmer’s dividend payout ratio (DPR) is 7.76%.
In other news, Director Alexis P. Michas sold 2,000 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $82.56, for a total value of $165,120.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.80% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in PKI. Keybank National Association OH purchased a new stake in PerkinElmer in the first quarter worth about $236,000. Raymond James & Associates grew its holdings in shares of PerkinElmer by 48.0% during the first quarter. Raymond James & Associates now owns 22,031 shares of the medical research company’s stock valued at $2,123,000 after buying an additional 7,141 shares during the last quarter. Clearbridge Investments LLC grew its holdings in shares of PerkinElmer by 39.5% during the first quarter. Clearbridge Investments LLC now owns 86,922 shares of the medical research company’s stock valued at $8,376,000 after buying an additional 24,599 shares during the last quarter. Private Advisor Group LLC purchased a new stake in shares of PerkinElmer during the second quarter valued at approximately $225,000. Finally, TD Asset Management Inc. grew its holdings in shares of PerkinElmer by 0.6% during the first quarter. TD Asset Management Inc. now owns 31,150 shares of the medical research company’s stock valued at $3,002,000 after buying an additional 200 shares during the last quarter. Institutional investors own 95.20% of the company’s stock.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Featured Article: Back-End Load
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.